相关实验视频

Updated: May 20, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

针对敏感和多药耐药的白血病细胞,使用一种新型的佐-伊萨结合剂

Chunmei Jin¹, Mahmoud Emam², Sabine M Klauck³

¹Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences Chemistry, Johannes Gutenberg University, Staudinger Weg 5, 55128, Mainz, Germany.

European journal of pharmacology

|March 23, 2025

概括

这项研究表明,一种新的佐 - 伊沙结合物G-5e有效地治疗了多药耐药的癌细胞. 它通过触发细胞死亡来起作用,并为克服药物耐药性的希望提供了希望.

科学领域:

药用化学医学化学
癌症生物学癌症生物学
药理学药理学是指药理学的学科.

背景情况:

松-伊沙丁合物在癌症治疗中表现有前途.
它们对抗多药耐药 (MDR) 瘤的疗效仍然未被探索.
了解抵抗机制对于开发新的癌症治疗方法至关重要.

研究的目的:

为了研究一种新的福-伊萨丁结合物G-5e对抗多药耐药癌细胞系的活性.
阐明G-5e活动背后的机制,包括抵押品敏感性.
评估G-5e在克服常见药物耐药性途径方面的潜力.

主要方法:

在已知抗药机制 (P-gp,BCRP,TP53,EGFR) 的细胞系中选G-5e.
在过度表达CEM/ADR5000细胞的P-糖蛋白中评估附带敏感性.
分析细胞周期进展,自标志物 (RND2,LC3B) 和转录组特征 (NF-κB,ERK1/2通路).

主要成果:

CEM/ADR5000细胞对G-5e表现出显著的过敏性 (附带敏感性).
通过RND2下调和LC3B上调,G-5e诱导了自细胞死亡.
在G0/G1阶段观察到细胞周期停止.
转录组分析显示NF-κB和ERK1/2通路的下调.

结论:

像G-5e这样的佐 - 伊沙丁合物显示出对抗多抗药性癌症的潜力.
RND2在调解对G-5e的抵押品敏感性方面发挥着重要作用.
G-5e调节自和关键信号通路的能力提供了对抗耐药瘤的有希望的策略.

关键词:

自细胞死亡自细胞死亡福兰 - 伊萨丁结合剂的结合物担保的敏感性担保的敏感性多种药物耐药性多种药物耐药性这是一种P-glycoprotein蛋白.

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...